Literature DB >> 11595134

Aberrant expression of p21(WAF1/CIP1) and p27(KIP1) in cervical carcinoma.

T H Cheung1, K W Lo, M M Yu, S F Yim, C S Poon, T K Chung, Y F Wong.   

Abstract

An immuno-histochemical study of p21 and p27 expression in cervical carcinoma was performed in 73 patients. Positive p21 and p27 staining was detected in 35.6 and 11% of tumour tissues, respectively. p21 expression was significantly correlated with advanced disease stage and negative human papilloma virus infection whilst positive p27 staining was not correlated with any clinical and pathological parameters studied. Kaplan-Meier estimation indicated that survival might be related to disease stage, tumour grade and p21 expression. Cox regression analysis confirmed that advanced stage disease and poorly differentiated tumour are independent prognostic factors for cervical carcinoma.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11595134     DOI： 10.1016/s0304-3835(01)00624-3

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  19 in total

1.  The opposite prognostic significance of nuclear and cytoplasmic p21 expression in resectable gastric cancer patients.

Authors:  Yefei Huang; Weimin Wang; Yansu Chen; Yulin Huang; Jianbing Zhang; Song He; Yongfei Tan; Fulin Qiang; Aiping Li; Oluf Dimitri Røe; Shouyu Wang; Yan Zhou; Jianwei Zhou
Journal:  J Gastroenterol       Date:  2013-10-15       Impact factor: 7.527

2.  Role of Cdk1 in the p53-independent abrogation of the postmitotic checkpoint by human papillomavirus E6.

Authors:  Weifang Zhang; Yingwang Liu; Ning Zhao; Hanxiang Chen; Lijun Qiao; Weiming Zhao; Jason J Chen
Journal:  J Virol       Date:  2014-12-17       Impact factor: 5.103

3.  Nucleolar GTP-binding Protein-1 (NGP-1) Promotes G1 to S Phase Transition by Activating Cyclin-dependent Kinase Inhibitor p21 Cip1/Waf1.

Authors:  Debduti Datta; Kumaraswamy Anbarasu; Suryaraja Rajabather; Rangasamy Sneha Priya; Pavitra Desai; Sundarasamy Mahalingam
Journal:  J Biol Chem       Date:  2015-07-09       Impact factor: 5.157

4.  Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7.

Authors:  Jongdae Lee; Tsung-Hsien Chuang; Vanessa Redecke; Liping She; Paula M Pitha; Dennis A Carson; Eyal Raz; Howard B Cottam
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-08       Impact factor: 11.205

Review 5.  p21 in cancer: intricate networks and multiple activities.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

Review 6.  Aberrant cell cycle regulation in cervical carcinoma.

Authors:  Young Tae Kim; Min Zhao
Journal:  Yonsei Med J       Date:  2005-10-31       Impact factor: 2.759

7.  Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer.

Authors:  Xi Xia; Quanfu Ma; Xiao Li; Teng Ji; Pingbo Chen; Hongbin Xu; Kezhen Li; Yong Fang; Danhui Weng; Yanjie Weng; Shujie Liao; Zhiqiang Han; Ronghua Liu; Tao Zhu; Shixuan Wang; Gang Xu; Li Meng; Jianfeng Zhou; Ding Ma
Journal:  BMC Cancer       Date:  2011-09-21       Impact factor: 4.430

8.  Somatic cell type specific gene transfer reveals a tumor-promoting function for p21(Waf1/Cip1).

Authors:  Yuhui Liu; Nancy Yeh; Xin-Hua Zhu; Margaret Leversha; Carlos Cordon-Cardo; Ronald Ghossein; Bhuvanesh Singh; Eric Holland; Andrew Koff
Journal:  EMBO J       Date:  2007-10-18       Impact factor: 11.598

9.  Small double-stranded RNA mediates the anti-cancer effects of p21WAF1/ClP1 transcriptional activation in a human glioma cell line.

Authors:  Zhiqiang Dong; Yamei Dang; Yirong Chen
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

10.  TRIM3, a tumor suppressor linked to regulation of p21(Waf1/Cip1.).

Authors:  Y Liu; R Raheja; N Yeh; D Ciznadija; A M Pedraza; T Ozawa; E Hukkelhoven; H Erdjument-Bromage; P Tempst; N P Gauthier; C Brennan; E C Holland; A Koff
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.